Patients Rare diseases, real opportunity: Why the UK’s next challenge... The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.
Patients Towards a healthier world: Momentum in UK health system tran... In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Lee-Ann Farrell, Head of National Programmes at Johnson & Johnson.
Market Access Health, growth & renewal: ABPI 2026 looks to UK’s future The Association of the British Pharmaceutical Industry (ABPI)'s flagship annual conference took place on Thursday, 23rd April.
Market Access Indication-specific pricing in England: Business as usual? Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.